Development of Integrin-Facilitated Bispecific Aptamer Chimeras for Membrane Protein Degradation
Journal of the American Chemical Society · 18.09.2024 · 146 (37) · 25490-25500
DOI: 10.1021/jacs.4c04794 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Chemical Society, online erschienen am 03.09.2024. Verfasst von Weidi Sun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engi…. Hauptthemen laut MEDLINE: Aptamers, Nucleotide, Receptors, Transferrin. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
The emergence of lysosome-targeting chimeras (LYTACs), which represents a promising strategy for membrane protein degradation based on lysosomal pathways, has attracted much attention in disease intervention and treatment. However, the expression level of commonly used lysosome-targeting receptors (LTRs) varies in different cell lines, thus limiting the broad applications of LYTACs. To overcome this difficulty, we herein report the development of integrin α3β1 (ITGA3B1)-facilitated bispecific aptamer chimeras (ITGBACs) as a platform for the degradation of membrane proteins. ITGBACs consist of two aptamers, one targeting ITGA3B1 and another binding to the membrane-associated protein of interest (POI), effectively transporting the POI into lysosomes for degradation. Our findings demonstrate that ITGBACs effectively eliminate pathological membrane proteins, such as CD71 and PTK7, inducing significant cell-cycle arrest and apoptosis and markedly inhibiting tumor growth in tumor-bearing mice models. Therefore, this work provides a novel and versatile membrane protein degradation platform, offering a promising targeted therapy based on tumor-specific LTRs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, Aptamer Engineering Center of Hunan Provi…
- Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
- School of Molecular Medicine, Hangzhou Institute for Advanced Study, UCAS, Hangzhou, Zhejiang 310024, China.
- Institute of Molecular Medicine (IMM), Renji Hospital, Shanghai Jiao Tong University School of Medicine, and College of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.
ORCID-Profile: Fengli Qu, Weihong Tan
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Health Commission of Zhejiang Province
- Research Funds of Hangzhou Institute for Advanced Study
- Pioneer Research and Development Program of Zhejiang
Zitieren
APA
Sun, W., Zhang, H., Xie, W., Ma, L., Dang, Y., Liu, Y., Li, L., Qu, F., & Tan, W. (2024). Development of Integrin-Facilitated Bispecific Aptamer Chimeras for Membrane Protein Degradation. Journal of the American Chemical Society, 146(37), 25490-25500. https://doi.org/10.1021/jacs.4c04794
Vancouver
Sun W, Zhang H, Xie W, Ma L, Dang Y, Liu Y, et al. Development of Integrin-Facilitated Bispecific Aptamer Chimeras for Membrane Protein Degradation. Journal of the American Chemical Society. 2024;146(37):25490-25500. doi:10.1021/jacs.4c04794
BibTeX
@article{Sun2024,
author = {Sun, Weidi and Zhang, Hui and Xie, Wanlin and Ma, Lele and Dang, Yang and Liu, Yuan and Li, Ling and Qu, Fengli and Tan, Weihong},
title = {Development of Integrin-Facilitated Bispecific Aptamer Chimeras for Membrane Protein Degradation},
journal = {Journal of the American Chemical Society},
year = {2024},
volume = {146},
number = {37},
pages = {25490--25500},
doi = {10.1021/jacs.4c04794}
}
EUVIMED